Zhang Renzhi, Zou Chun, Zeng Liang, Zhang Yongchang
Department of Medical Oncology, Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang.
Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Curr Opin Oncol. 2025 Jan 1;37(1):40-47. doi: 10.1097/CCO.0000000000001098. Epub 2024 Sep 5.
To evaluate and summarize the current clinical efficacy, safety, treatment patterns, and potential biomarkers, to guide future treatment strategies for nonsmall cell lung cancer (NSCLC), improve patient prognosis, and provide a scientific basis for personalized therapy.
In recent years, the class of immune checkpoint inhibitors (ICIs), with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors at the helm, has catalyzed groundbreaking advancements within the perioperative treatment milieu for NSCLC. With the positive results of several phase III clinical trials, perioperative immunotherapy has been confirmed to significantly reduce the risk of postoperative recurrence in resectable NSCLC, becoming the new standard for perioperative treatment of stages II to III NSCLC. With the advent of the perioperative immunotherapy era, clinical issues such as the selection of the treatment population, the choice of regimen, the duration of treatment, whether patients with pCR need further adjuvant therapy, and the comprehensive management of patients throughout the perioperative period have attracted widespread attention.
The perioperative treatment of NSCLC has fully entered the era of immunotherapy. Multiple clinical studies have confirmed that perioperative immunotherapy can significantly improve the survival benefit of resectable stages II to III NSCLC, establishing a new standard for the perioperative treatment of stages II to III NSCLC.
评估并总结当前非小细胞肺癌（NSCLC）的临床疗效、安全性、治疗模式及潜在生物标志物，以指导未来的治疗策略，改善患者预后，并为个体化治疗提供科学依据。
近年来，以程序性死亡蛋白1/程序性死亡配体1（PD-1/PD-L1）抑制剂为首的免疫检查点抑制剂（ICI）类药物，在NSCLC围手术期治疗领域引发了突破性进展。随着多项III期临床试验取得阳性结果，围手术期免疫治疗已被证实可显著降低可切除NSCLC患者的术后复发风险，成为II至III期NSCLC围手术期治疗的新标准。随着围手术期免疫治疗时代的到来，治疗人群的选择、治疗方案的选择、治疗持续时间、达到病理完全缓解（pCR）的患者是否需要进一步辅助治疗以及围手术期患者的综合管理等临床问题受到广泛关注。
NSCLC的围手术期治疗已全面进入免疫治疗时代。多项临床研究证实，围手术期免疫治疗可显著提高可切除II至III期NSCLC患者的生存获益，确立了II至III期NSCLC围手术期治疗的新标准。
